Drug found to slow Alzheimer’s by up to 60 percent in trial | Canada News Media
Connect with us

Health

Drug found to slow Alzheimer’s by up to 60 percent in trial

Published

 on

A new drug has been hailed as a “breakthrough” after it was found to slow the progression of Alzheimer’s disease by 60 percent if started when patients are in the earliest stages of the brain-wasting disease, according to a new study.

The drug, donanemab, has been shown to slow progression of memory and thinking problems by about a third, but that rate doubles to 60 percent if the drug is started when patients are only mildly impaired, according to new trial data presented by Eli Lilly on Monday at the Alzheimer’s Association International Conference in Amsterdam.

The full analysis presented by the American pharmaceutical company showed results were less robust for older, later-stage patients as well as those with higher levels of a protein called tau, which has been linked to Alzheimer’s disease progression.

The findings underscored that “earlier detection and diagnosis can really change the trajectory of this disease”, Anne White, president of neuroscience at Eli Lilly, told the Reuters news agency.

The drug consists of injecting donanemab, an intravenous antibody designed to remove deposits of a protein called beta amyloid from the brains of Alzheimer’s patients.

Donanemab’s treatment effect continued to increase relative to placebos over the course of the 18-month trial, even for participants who had been taken off the drug after their levels of amyloid deposits fell significantly.

“At the end of the trial, the average patient had been without the drug for seven months, and yet they continued to benefit,” White said.

The company expected the US Food and Drug Administration to decide by the end of this year whether to approve donanemab. It said submissions to other global regulators were under way and most will be completed by year’s end.

More than 55 million people worldwide are affected by dementia, and the number is projected to rise to 139 million people by 2050, according to Alzheimer’s Disease International, the worldwide federation of Alzheimer’s associations.

The new medication has been welcomed with enthusiasm by patients. Joe Montminy, who was diagnosed with early onset Alzheimer’s disease at 54, said the disease has kept “changing the core of who I am” over the past six years.

“Everyday things like projects around the house or something as simple as texting now take me two to three times longer than they did just six months ago,” Montminy told Al Jazeera.

His wife and mother noticed changes in his personality, including mood swings, impulsiveness and a short temper, which he says are “out of character”.

“I’m very excited about having these new treatments because getting six months, nine months or more quality time with my wife, my sons and my friends would be priceless,” Montminy said.

Side effects

Al Jazeera’s Step Vaessen, reporting from Amsterdam, said the findings have been hailed as a “breakthrough” at the conference but “real division” remains within the scientific community.

The full analysis also highlighted side effects including brain swelling. Brain bleeding occurred in 31 percent of the donanemab group and about 14 percent of the placebo group.

The deaths of three trial patients were linked to the treatment, researchers reported.

“Scientists I spoke to who are not here at the conference say that [the drug] is too driven by the pharmaceutical industry,” she said. “Big pharma is pushing for a new medicine because it’s a huge group of patients they are targeting.”

An additional downside was the cost of the medication. “It is estimated that it’s going to cost around $26,000 per patient per year,” Vaessen said.

More than 6 million Americans are living with Alzheimer’s, and that number is projected to rise to nearly 13 million by 2050, according to the Alzheimer’s Association.

Another recently approved drug, Leqembi from Japanese drugmaker Eisai, also comes with serious safety concerns, including brain swelling and bleeding.

Scientists said that while these drugs may mark a new era in Alzheimer’s therapy, huge questions remain about which patients should try them and how much benefit they will really notice.

 

Source link

Continue Reading

Health

Canada to donate up to 200,000 vaccine doses to combat mpox outbreaks in Africa

Published

 on

 

The Canadian government says it will donate up to 200,000 vaccine doses to fight the mpox outbreak in Congo and other African countries.

It says the donated doses of Imvamune will come from Canada’s existing supply and will not affect the country’s preparedness for mpox cases in this country.

Minister of Health Mark Holland says the donation “will help to protect those in the most affected regions of Africa and will help prevent further spread of the virus.”

Dr. Madhukar Pai, Canada research chair in epidemiology and global health, says although the donation is welcome, it is a very small portion of the estimated 10 million vaccine doses needed to control the outbreak.

Vaccine donations from wealthier countries have only recently started arriving in Africa, almost a month after the World Health Organization declared the mpox outbreak a public health emergency of international concern.

A few days after the declaration in August, Global Affairs Canada announced a contribution of $1 million for mpox surveillance, diagnostic tools, research and community awareness in Africa.

On Thursday, the Africa Centres for Disease Control and Prevention said mpox is still on the rise and that testing rates are “insufficient” across the continent.

Jason Kindrachuk, Canada research chair in emerging viruses at the University of Manitoba, said donating vaccines, in addition to supporting surveillance and diagnostic tests, is “massively important.”

But Kindrachuk, who has worked on the ground in Congo during the epidemic, also said that the international response to the mpox outbreak is “better late than never (but) better never late.”

“It would have been fantastic for us globally to not be in this position by having provided doses a much, much longer time prior than when we are,” he said, noting that the outbreak of clade I mpox in Congo started in early 2023.

Clade II mpox, endemic in regions of West Africa, came to the world’s attention even earlier — in 2022 — as that strain of virus spread to other countries, including Canada.

Two doses are recommended for mpox vaccination, so the donation may only benefit 100,000 people, Pai said.

Pai questioned whether Canada is contributing enough, as the federal government hasn’t said what percentage of its mpox vaccine stockpile it is donating.

“Small donations are simply not going to help end this crisis. We need to show greater solidarity and support,” he said in an email.

“That is the biggest lesson from the COVID-19 pandemic — our collective safety is tied with that of other nations.”

This report by The Canadian Press was first published Sept. 13, 2024.

Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Health

How many Nova Scotians are on the doctor wait-list? Number hit 160,000 in June

Published

 on

 

HALIFAX – The Nova Scotia government says it could be months before it reveals how many people are on the wait-list for a family doctor.

The head of the province’s health authority told reporters Wednesday that the government won’t release updated data until the 160,000 people who were on the wait-list in June are contacted to verify whether they still need primary care.

Karen Oldfield said Nova Scotia Health is working on validating the primary care wait-list data before posting new numbers, and that work may take a matter of months. The most recent public wait-list figures are from June 1, when 160,234 people, or about 16 per cent of the population, were on it.

“It’s going to take time to make 160,000 calls,” Oldfield said. “We are not talking weeks, we are talking months.”

The interim CEO and president of Nova Scotia Health said people on the list are being asked where they live, whether they still need a family doctor, and to give an update on their health.

A spokesperson with the province’s Health Department says the government and its health authority are “working hard” to turn the wait-list registry into a useful tool, adding that the data will be shared once it is validated.

Nova Scotia’s NDP are calling on Premier Tim Houston to immediately release statistics on how many people are looking for a family doctor. On Tuesday, the NDP introduced a bill that would require the health minister to make the number public every month.

“It is unacceptable for the list to be more than three months out of date,” NDP Leader Claudia Chender said Tuesday.

Chender said releasing this data regularly is vital so Nova Scotians can track the government’s progress on its main 2021 campaign promise: fixing health care.

The number of people in need of a family doctor has more than doubled between the 2021 summer election campaign and June 2024. Since September 2021 about 300 doctors have been added to the provincial health system, the Health Department said.

“We’ll know if Tim Houston is keeping his 2021 election promise to fix health care when Nova Scotians are attached to primary care,” Chender said.

This report by The Canadian Press was first published Sept. 11, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Health

Newfoundland and Labrador monitoring rise in whooping cough cases: medical officer

Published

 on

 

ST. JOHN’S, N.L. – Newfoundland and Labrador‘s chief medical officer is monitoring the rise of whooping cough infections across the province as cases of the highly contagious disease continue to grow across Canada.

Dr. Janice Fitzgerald says that so far this year, the province has recorded 230 confirmed cases of the vaccine-preventable respiratory tract infection, also known as pertussis.

Late last month, Quebec reported more than 11,000 cases during the same time period, while Ontario counted 470 cases, well above the five-year average of 98. In Quebec, the majority of patients are between the ages of 10 and 14.

Meanwhile, New Brunswick has declared a whooping cough outbreak across the province. A total of 141 cases were reported by last month, exceeding the five-year average of 34.

The disease can lead to severe complications among vulnerable populations including infants, who are at the highest risk of suffering from complications like pneumonia and seizures. Symptoms may start with a runny nose, mild fever and cough, then progress to severe coughing accompanied by a distinctive “whooping” sound during inhalation.

“The public, especially pregnant people and those in close contact with infants, are encouraged to be aware of symptoms related to pertussis and to ensure vaccinations are up to date,” Newfoundland and Labrador’s Health Department said in a statement.

Whooping cough can be treated with antibiotics, but vaccination is the most effective way to control the spread of the disease. As a result, the province has expanded immunization efforts this school year. While booster doses are already offered in Grade 9, the vaccine is now being offered to Grade 8 students as well.

Public health officials say whooping cough is a cyclical disease that increases every two to five or six years.

Meanwhile, New Brunswick’s acting chief medical officer of health expects the current case count to get worse before tapering off.

A rise in whooping cough cases has also been reported in the United States and elsewhere. The Pan American Health Organization issued an alert in July encouraging countries to ramp up their surveillance and vaccination coverage.

This report by The Canadian Press was first published Sept. 10, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version